Caribou Biosciences Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Caribou Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $12. The average 1-year stock price forecast is 552.17% higher than the current stock price, while the lowest is $4.00 (+117.39%) and the highest is $32 (+1,639.13%).

Price Target: $12 (+552.17%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$12	$10	$32
Change	+117.39%	+552.17%	+443.48%	+1639.1%

Analyst Ratings

The average analyst rating for Caribou Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	6	6	6	7	7	6
Buy	1	1	1	1	1	1
Hold	1	1	1	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Maintains $11	Buy	Maintains	$11	+497.83%	May 26, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $6	Buy	Maintains	$6	+226.09%	May 13, 2026
Luca Issi RBC Capital	RBC Capital	Buy Maintains $10	Buy	Maintains	$10	+443.48%	May 8, 2026
Yigal Nochomovitz Citi	Citi	Buy Maintains $8	Buy	Maintains	$8	+334.78%	May 8, 2026
Jonathan Miller Evercore ISI	Evercore ISI	Buy Maintains $11 → $13	Buy	Maintains	$11 → $13	+606.52%	Mar 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

25.66M

from 11.16M

129.99%

from 11.16M

Revenue Next Year

30.08M

from 25.66M

17.20%

from 25.66M

EPS This Year

-1.26

from -

EPS Next Year

-1.40

from -1.26

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	9.60M	13.85M	34.48M	9.99M	11.16M	25.66M
Revenue Growth	-22.35%	44.31%	148.91%	-71.01%	11.66%	129.99%
Gross Profit	-42.66M	-68.38M	-77.60M	-120.16M	-96.36M	25.66M
Gross Margin	-444.44%	-493.68%	-225.07%	-1,202.31%	-863.55%	100.00%
Operating Income	-66.98M	-106.40M	-116.06M	-166.62M	-133.92M	-131.70M
Net Income	-66.92M	-99.42M	-102.07M	-149.11M	-148.13M	-125.20M
EPS	-	-	-	-	-	-1.26
Free Cash Flow	-33.46M	-56.11M	-64.36M	-87.71M	-69.80M	-141.59M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	100.0M
Avg	25.7M
Low	9.9M

Revenue Growth

Revenue Growth	2026	2027	2028
High	796.1%
Avg	130.0%
Low	-11.3%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.26
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-